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Dysregulation of myocardial redox signaling is involved in the pathophysiology of multiple cardiac diseases.1 
Nicotinamide adenine dinucleotide phosphate (NADPH) ox-
idases are major enzymatic sources of reactive oxygen spe-
cies in the heart2 and have been linked in the past to cardiac 
pathologies such as atrial fibrillation,3–5 myocardial hyper-
trophy,6 heart failure,7 and others.8 Metabolic abnormalities 
such as obesity or diabetes mellitus are associated with in-
creased NADPH oxidases activity in the cardiovascular sys-
tem8,9 although the underlying mechanisms of these links are 
controversial.10,11 Because pharmacological treatments able 
to suppress myocardial NADPH oxidases (eg, statins as a 
part of their pleiotropic effects in the human heart5) have 
failed to prevent cardiac disease progression in humans,12 
Translational Research
Rationale: Adiponectin has anti-inflammatory effects in experimental models, but its role in the regulation of 
myocardial redox state in humans is unknown. Although adiponectin is released from epicardial adipose tissue 
(EpAT), it is unclear whether it exerts any paracrine effects on the human myocardium.
Objective: To explore the cross talk between EpAT-derived adiponectin and myocardial redox state in the human 
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Methods and Results: EpAT and atrial myocardium were obtained from 306 patients undergoing coronary artery 
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to reduced myocardial nicotinamide adenine dinucleotide phosphate oxidase–derived O2−, whereas circulating 
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tissue, we demonstrated that adiponectin suppresses myocardial nicotinamide adenine dinucleotide phosphate 
oxidase activity, by preventing AMP kinase–mediated translocation of Rac1 and p47phox from the cytosol to the 
membranes. Induction of O2− production in H9C2 cardiac myocytes led to the release of a transferable factor 
able to induce peroxisome proliferator-activated receptor-γ–mediated upregulation of ADIPOQ expression in 
cocultured EpAT. Using a NOX2 transgenic mouse and a pig model of rapid atrial pacing, we found that oxidation 
products (such as 4-hydroxynonenal) released from the heart trigger peroxisome proliferator-activated receptor-
γ–mediated upregulation of ADIPOQ in EpAT.
Conclusions: We demonstrate for the first time in humans that adiponectin directly decreases myocardial 
nicotinamide adenine dinucleotide phosphate oxidase activity via endocrine or paracrine effects. Adiponectin 
expression in EpAT is controlled by paracrine effects of oxidation products released from the heart. These effects 
constitute a novel defense mechanism of the heart against myocardial oxidative stress.  (Circ Res. 2016;118:842-
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better understanding of the endogenous mechanisms regulat-
ing NADPH oxidases in the human heart is essential for the 
development of new therapeutic strategies to target myocar-
dial redox state.13
Adipose tissue affects the cardiovascular system by secret-
ing a wide range of bioactive products known as adipokines.14 
Adiponectin is an important adipokine with anti-inflammatory15 
and antioxidant effects on the vasculature16 and the heart of 
experimental models,17 but its role in the regulation of myo-
cardial redox state in humans is unknown.
In healthy individuals, low circulating adiponectin is as-
sociated with increased cardiovascular risk18; however, in in-
dividuals with ischemic heart disease (IHD), adiponectin gene 
expression in adipose tissue is increased14 and high circulating 
adiponectin predicts adverse clinical outcome.19 Importantly, 
given that the human heart is surrounded by biologically ac-
tive epicardial adipose tissue (EpAT), adiponectin released 
from it may exert additional paracrine effects on the underly-
ing myocardium in a similar way perivascular adipose tissue 
exerts paracrine effects on the vascular wall,20 a concept that 
has not been previously explored.
In this study, we explore the role of adiponectin in the 
regulation of myocardial redox state in patients with IHD, and 
we characterize the underlying molecular mechanisms medi-
ating adiponectin’s effects on the heart. In addition, we define 
the mechanisms controlling peroxisome proliferator-activated 
receptor (PPAR)-γ/adiponectin signaling in human EpAT, and 
we introduce the novel concept of an inside to outside signal-
ing released from the human heart in conditions of increased 
myocardial oxidative stress, which controls the biosynthetic 
activity of the neighboring EpAT.
Methods
Study Population
The study population consisted of 306 patients undergoing coronary 
artery bypass grafting surgery; 247 of these were included in the 
Clinical Associations Studies and 59 into the ex vivo arm of the study. 
Blood samples were obtained on the morning of surgery, whereas 
samples of myocardium and adipose tissue were collected during 
surgery, as described below. Myocardial and adipose tissue samples 
were used for ex vivo experiments to address the mechanisms regu-
lating the cross talk between EpAT and human myocardium as de-
scribed below. Exclusion criteria were any inflammatory, infectious, 
liver or renal disease, or malignancy. Patients receiving nonsteroidal 
anti-inflammatory drugs, dietary supplements, or antioxidant vita-
mins were also excluded.
Design of the Clinical Associations Studies
In 247 patients undergoing coronary artery bypass grafting, blood 
samples were collected at the morning of surgery for measuring cir-
culating adiponectin and other biomarkers as well as for DNA extrac-
tion and genotyping. Samples of right atrial appendage obtained from 
the cannulation site5 were used to quantify NADPH oxidase–derived 
superoxide anions (O2−), aiming to relate it with circulating adiponec-
tin and the expression of ADIPOQ gene (encoding adiponectin) in 
different adipose tissue depots. These myocardial samples were also 
used to study the myocardial expression of ADIPOQ and adiponectin 
receptors. In addition, EpAT from the atrioventricular groove and tho-
racic adipose tissue (ThAT) from the outer surface of the pericardi-
um14 were collected and used to quantify the expression of ADIPOQ 
and other target genes, aiming to search for predictors of myocardial 
redox state as described below. More detail on samples collection and 
processing is provided in the Online Data Supplement.
Blood Sampling and Measurement of Circulating 
Biomarkers
Venous blood samples were obtained after 8 hours of fasting, on the 
morning of the operation, and used for measurement of circulating 
biomarkers (as described in the Online Data Supplement).
DNA Extraction and Genotyping
Genomic DNA extraction from whole blood and genotyping were 
performed using standard methods (as described in the Online Data 
Supplement).
Myocardial Superoxide Measurements
Myocardial O2− production was measured in right atrial appendage 
samples using lucigenin (5 μmol/L)–enhanced chemiluminescence 
(as described in the Online Data Supplement).
RNA Isolation and Quantitative Real-Time-
Polymerase Chain Reaction
Samples of adipose tissue and right atrial appendage were used for 
RNA extraction and gene expression studies (as described in the 
Online Data Supplement).
Ex Vivo Experiments With Human Myocardium
To examine the direct effects of adiponectin on myocardial O2− pro-
duction, human myocardial tissue from the right atrial appendage 
was incubated ex vivo for 2 hours with/without adiponectin in the 
presence/absence of the pharmacological inhibitor of AMP-kinase 
(AMPK), compound C (CC). Briefly, myocardial tissue was washed 
in ice-cold Krebs HEPES buffer, and then cut into thin strips contain-
ing all myocardial layers. The tissue was first equilibrated for 20 min-
utes in Krebs HEPES buffer pH 7.35 at 37°C, and then incubated for 
2 hours in the presence or absence of recombinant full-length adipo-
nectin 0.3 μmol/L (10 μg/mL; BioVendor)±CC (10 μmol/L). The ef-
fect of adiponectin on myocardial O2− (basal and NADPH-stimulated 
O2−) was quantified by lucigenin (5 μmol/L)–enhanced chemilumi-
nescence (as described in the Online Data Supplement ). To estimate 
the effect of adiponectin on NADPH oxidase–derived O2−,we used 
the pan-NADPH oxidase inhibitor Vas287021 (40 µmol/L; Sigma 
Aldrich).
Ex Vivo Experiments With Human Adipose Tissue
Samples of ThAT and EpAT obtained from patients in the ex vivo 
study arm were used to estimate the effects of lipid oxidation prod-
ucts on ADIPOQ gene expression in an ex vivo bioassay. Briefly, adi-
pose tissue was isolated and washed in sterile phosphate buffer saline 
(PBS). The samples of adipose tissue of each type were transferred to 
the laboratory within 30 minutes from harvesting. The samples were 
then cut into ≈1- to 2-mm3 cubes, washed, and equilibrated for 2 hours 
at 37°C in Medium-199 containing HEPES (25 mmol/L), gentamycin 
105 μmol/L (50 μg/mL), and fatty acid–free BSA (1%), in the pres-
ence of protease inhibitor (Roche Applied Science) in a cell culture 
incubator with 5% CO2 atmosphere. At the end of the equilibration 
period, the media was replaced by fresh media (1 mL/200 mg tissue) 
Nonstandard Abbreviations and Acronyms
4HNE 4-hydroxynonenal
BNP brain natriuretic peptide
CABG coronary artery bypass grafting
CC compound C
EpAT epicardial adipose tissue
IHD ischemic heart disease
NADPH nicotinamide adenine dinucleotide phosphate
PMA phorbol-12-myristate-13-acetate
PPAR peroxisome proliferator-activated receptor
ThAT thoracic adipose tissue
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and incubated for 16 hours as above but in the presence or absence 
of (1) H2O2 (100 μmol/L), (2) malonyldialdehyde (1 mmol/L), (3) 
4-hydroxynonenal (HNE, 30 μmol/L)±T0070907 (10 μmol/L, an 
inhibitor of PPAR-γ). For the samples treated with T0070907, this agent 
was also used during the equilibration period. At the end of the 16-hour 
incubation period, AT samples were filtered, collected, and stored at 
−80°C until analysis. Quantitative real-time-polymerase chain reactions 
were performed (as described in the Online Data Supplement) to 
determine ADIPOQ, PPAR-γ, and CD36 gene expression.
Cocultures of Rat EpAT With H9C2 Cells
To evaluate the interaction between AT and myocardium, the rat car-
diac myocyte–derived cell line H9c2 was coincubated with rat EpAT 
ex vivo. Briefly, H9c2 cells were differentiated to cardiac myocytes 
in Dulbecco’s Modified Eagle Medium (Sigma-Aldrich) supplement-
ed with 1% horse serum (Sigma-Aldrich). The cells were exposed 
to either NADPH (100 μmol/L) or phorbol-12-myristate-13-acetate 
(PMA; 160 nmol/L) for 2 hours as a means to induce O2− genera-
tion from NADPH oxidases. Freshly collected rat EpAT from female 
Wistar rats was then added to the culture medium and coincubated 
with H9c2-derived cardiac myocytes with or without NADPH (100 
μmol/L; n=7) or PMA 160 nmol/L (n=7) for 16 hours. To control for 
direct effects of NADPH or PMA on adipose tissue, EpAT was also 
incubated alone in the presence or absence of NADPH (100 μmol/L) 
or PMA (160 nmol/L). To prevent any direct effects of endogenous 
O2− in EpAT, additional interventions with NADPH (100 μmol/L) and 
polyethylene glycol (PEG)-SOD (300 U/mL, a scavenger of O2−) or 
Vas2870 (10 nmol/L, an inhibitor of NADPH oxidases) were includ-
ed. At the end of the incubation period, EpAT was collected for gene 
expression studies (as described in the Online Data Supplement).
Measurement of Intracellular NADP/NADPH 
Levels
Intracellular NADP/NADPH levels were measured using a commer-
cially available fluorometric assay (Abcam kit, Cambridge, United 
Kingdom) as described in the Online Data Supplement.
Western Blots in Human Myocardial Samples
Western blotting was performed as described in the Online Data 
Supplement.
Measurement of Myocardial Rac1 Activation and 
Membrane Translocation Experiments
Rac1 activation and membrane translocation of Rac1 and p47phox 
were determined in right atrial appendage samples, as previously de-
scribed22 (Online Data Supplement).
Animal Studies
Mouse Model
Cardiac myocyte–specific NOX2-transgenic mice23 (mNOX2-tg; 
Online Data Supplement) were used as a model of chronically in-
creased myocardial oxidative stress to test the impact of increased 
myocardial Nox2-derived O2− production on adiponectin expression 
in subcutaneous and pericardial adipose tissue (attached to the apex 
of the heart).
Twenty-week-old transgenic male mice and wild-type littermate 
controls were euthanized, and whole heart samples and samples of 
subcutaneous and pericardial AT were harvested and studied.
Pig Model
Given the limitations related to the study of pericardial AT in mice 
(limited amount of tissue, not always present), we used a larger 
mammal model (pig), whose EpAT is directly attached on the heart 
muscle, mimicking the interaction between myocardium and EpAT 
in humans. To induce a chronic increase in oxidative stress in the 
atrial myocardium,4 we used a standardized protocol of rapid atrial 
pacing for 4 weeks and collected EpAT from the posterior left atri-
um at the end of this period. Subcutaneous AT was used as a control 
depot. More details on the pig model are provided in the Online Data 
Supplement.
Myocardial tissue samples from the 2 animal models were ho-
mogenized and used for lucigenin-enhanced chemiluminescence 
experiments to assess myocardial NADPH oxidases activity (as de-
scribed in the Online Data Supplement) and to blot for 4HNE and 
malonyldialdehyde protein adducts (antibodies by Abcam). RNA was 
extracted from myocardial and AT samples and used for gene expres-
sion studies (as described in the Online Data Supplement).
Statistical Analysis
Continuous variables were tested for normal distribution using 
Kolmogorov–Smirnov test. Non-normally distributed variables were 
log-transformed for analysis. In the Clinical Associations Study arm, 
continuous variables among 3 groups were compared using 1-way 
ANOVA followed by the Bonferroni post hoc test for individual com-
parisons, whereas comparisons between 2 groups were performed 
by unpaired t tests. Categorical variables were compared using the 
χ2 test as appropriate. Correlations between continuous variables 
were assessed by bivariate analysis, and the Pearson coefficient was 
estimated.
For the ex vivo experiments (in which serial segments from the 
same right atrial appendage were incubated with multiple interven-
tions), we performed repeated-measures ANOVA and paired t tests 
for individual comparisons, followed by the Bonferroni post hoc cor-
rection for multiple testing as appropriate. In the Clinical Associations 
study arm, correlations between continuous variables were tested by 
calculating the Pearson correlation coefficient. Multivariable linear 
regression was performed by using log(NADPH-stimulated O2-) or 
log(serum adiponectin) as dependent variables and by using demo-
graphic/biological variables that showed a significant association 
with the dependent variable in univariate analysis at the level of 15% 
as independent variables.
For the animal studies, comparisons of mNOX2-tg versus wild-
type mice or rapid atrial pacing versus sham were performed using un-
paired t test of the log-transformed values for the respective variables. 
Power calculations are provided in the Online Data Supplement. All 
statistical tests were performed with SPSS version 20.0, and values of 
P<0.05 were considered statistically significant.
Results
Interactions Between Adiponectin and Myocardial 
NADPH Oxidases Activity in Patients With IHD
The characteristics of the patients included in the Clinical 
Associations Studies are presented in the Table. In this co-
hort of patients with IHD, we first explored the association 
between adiponectin levels and myocardial redox state. We 
observed a positive association between circulating adipo-
nectin and myocardial NADPH-stimulated O2− (Figure 1A), 
as well as between circulating adiponectin and malonyldi-
aldehyde (Figure 1B), a plasma marker of oxidative stress. 
However, there was no significant association between 
adiponectin and either interleukin-6 (Figure 1C) or high-
sensitivity C-reactive protein (Figure 1D), suggesting that 
systemic inflammation does not confound the association 
between circulating adiponectin and myocardial NADPH 
oxidases activity. We also observed a significant association 
between plasma brain natriuretic peptide (BNP) and circu-
lating adiponectin (Figure 1E), but not between BNP and 
NADPH-stimulated O2− in the myocardium (Online Table I) 
or plasma malonyldialdehyde (r=0.147; P=0.092). To fur-
ther explore the association between myocardial redox state 
and serum adiponectin, we performed univariate analysis 
followed by multivariable analysis searching for predictors 
of myocardial NADPH oxidases-derived O2− (Online Table 
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I), confirming that the correlation between circulating adi-
ponectin and myocardial NADPH oxidases activity is inde-
pendent of BNP and other potential confounders (Figure 1A; 
Online Table I). In addition, this was independent of medi-
cation such as statins (βst=−0.314; P=0.0001), antiplatelet 
treatment (βst=−0.179; P=−0.29), β-blockers (βst=0.013; 
P=0.877), calcium channel blockers (βst=−0.019; P=0.807), 
or angiotensin-converting enzyme inhibitor/ angiotensin re-
ceptor blocker (βst=0.016; P=0.833), with R2 for the model 
0.238. Interestingly, serum levels of adiponectin or ADIPOQ 
gene expression in EpAT were not related with the incidence 
of postoperative atrial fibrillation (data not shown), which 
we have previously shown to be increased in patients with 
high atrial NADPH-oxidases activity.5
To further explore the association between adiponectin 
and myocardial redox state, we genotyped our study popu-
lation for 2 functional single nucleotide polymorphisms 
in the ADIPOQ locus encoding adiponectin (both single 
nucleotide polymorphisms with known effect on adiponec-
tin levels), located in the ADIPOQ locus (rs266717) and 
in the promoter region (rs17366568).24,25 We found that the 
number of rs266717G and rs17366568T alleles was posi-
tively associated with serum adiponectin (Figure 2A) and 
negatively associated with myocardial NADPH oxidases 
activity (Figure 2B). This implies that low adiponectin pro-
duction in human AT is causally associated with higher myo-
cardial NADPH oxidases activity. Furthermore, there was a 
significant effect of the single nucleotide polymorphisms on 
the expression of ADIPOQ gene in ThAT (Figure 2C), but 
this was not observed in EpAT (Figure 2D), suggesting that 
local mechanisms may over-ride the influence of genetic 
background on ADIPOQ gene expression in EpAT but not in 
remote adipose tissue depots such as ThAT.
We next examined whether obesity and adipose tissue dis-
tribution alter the regulation of ADIPOQ gene expression in 
different adipose tissue depots. We confirmed that ADIPOQ 
gene expression in ThAT was strongly inversely correlated 
with waist:hip ratio and body mass index, whereas PPAR-
γ expression was similarly correlated with waist:hip ratio 
(although its association with body mass index was borderline 
significant; Online Figure IA–ID). However, these associa-
tions were not present in EpAT (Online Figure IE–IH). These 
discordant findings between EpAT and ThAT suggest that 
PPAR-γ/adiponectin signaling in EpAT is controlled by local 
mechanisms, possibly originating in the heart, rather than by 
systemic effects related to obesity and insulin resistance.
Importantly, there was a positive association between 
myocardial NADPH-stimulated O2− and the expression of 
both ADIPOQ (Figure 2E) and PPAR-γ genes (Figure 2F) 
in EpAT, suggesting that increased myocardial O2− may in-
fluence the expression of ADIPOQ in EpAT, possibly by 
regulating PPAR-γ expression. ADIPOQ gene expression is 
known to be partly under the control of PPAR-γ signaling. 
This was confirmed by the association between log(PPAR-γ) 
and log(ADIPOQ) gene expression in EpAT of patients with 
IHD (r=0.598; P<0.0001).
To explore whether myocardial resistance to adiponectin 
is responsible for the positive association between myocar-
dial redox state and adiponectin levels (systemic and EpAT 
expression), we studied the expression of ADIPOQ and adi-
ponectin receptors (ADIPOR1, ADIPOR2, and CDH13) in the 
myocardium of patients with advanced coronary atheroscle-
rosis. There was no association between myocardial NADPH 
oxidases activity and ADIPOQ gene expression (Figure 2G), 
whereas there was a positive association between myocardial 
NADPH oxidase activity and ADIPOR1 (but not ADIPOR2 
or CDH13; Figure 2H), suggesting that in the presence of in-
creased myocardial reactive oxygen species generation, there 
is upregulation of ADIPOR1 in human myocardium and an 
upregulation of ADIPOQ gene in EpAT.
Adiponectin Directly Decreases NADPH Oxidases 
Activity in the Human Myocardium
To examine whether adiponectin has the ability to affect myo-
cardial redox state in humans, myocardial tissue from patients 
with IHD (Table) was incubated with adiponectin (10 μg/mL) 
for 2 hours. Exogenous adiponectin rapidly induced phosphor-
ylation of AMPK at the activatory site Thr172 (Figure 3A) 
and the downstream target acetyl-coA carboxylase, via phos-
phorylation at Ser79 (Figure 3B). As expected, the observed 
effects on acetyl-coA carboxylase phosphorylation, a marker 
of AMPK activity, were prevented by the AMPK inhibitor CC 
Table. Demographic Characteristics of Study Participants
Clinical Associations Studies Ex Vivo Studies
Participants (n) 247 59
Age, y 66.8±0.6 69.1±1.5
Gender (men) 200 42
Hypertension, % 66.9 74.6
Dyslipidemia, % 49.8 79.7*
Diabetes mellitus, % 32.5 30.5
Smoking (active/ex) 28.2/43.3 13.6/54.2
BMI, kg/m2 27.5±0.27 29.5±0.6*
Cholesterol, mmol/L 4.34±0.2 5.70±0.6*
HDL, mmol/L 0.94±0.04 1.30±0.20*
Triglycerides, mmol/L† 1.39 (1.06–1.80) 1.20 (0.80–1.74)
Body surface area, m2 1.89±0.18 1.87±0.08
Waist circumference, cm 99.24±0.85 100.11±1.99
Waist:hip ratio 1.08±0.02 0.99±0.01*
Glucose, mmol/L 7.28±0.39 6.39±0.26*
HOMA-IR 5.43±1.65 9.27±1.43*
BNP, pg/mL 145±29 140±34
Medication
  ACEi/ARBs 49.1/15.0 36.4/7.3
  β-blockers 68.4 63.6
  Aspirin/clopidogrel 64.4/44.2 72.7/25.5
  Statins 66.2 76.4
  CCBs 20.5 32.7*
  Diuretics 20.7 25.5
ACEi/ARBs indicates angiotensin-converting enzyme inhibitors/angiotensin 
receptor blockers; BMI, body mass index; BNP, brain natriuretic peptide; 
CCBs, calcium channel blockers; HDL, high-density lipoprotein; and HOMA-IR, 
homeostatic model of insulin resistance.
*P<0.05 vs population in Clinical Associations studies.
†Values expressed as median (25th–75th percentile).
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(Figure 3A and 3B). Similarly, adiponectin induced a rapid 
reduction of myocardial O2− production that was reversed 
by CC (Figure 3C). Importantly, adiponectin suppressed 
the Vas2870-inhibitable fraction of myocardial O2− in a CC-
inhibitable manner (Figure 3D), suggesting that adiponectin 
inhibits NADPH oxidase activity via an AMPK-mediated 
mechanism. These AMPK-dependent effects of adiponectin 
were also confirmed in dihydroethidium staining experiments; 
adiponectin reduced both the total and the Vas2870-inhibitable 
dihydroethidium fluorescence (Figure 3E–3G). Adiponectin 
did not have any effects on the gene expression or protein 
levels of Nox isoforms or any NADPH oxidase subunits in 
human myocardium (Online Figure II), but prevented the ac-
tivation of Rac1 (reduced the GTP-Rac1/total Rac1) and its 
membrane translocation (Figure 3H and 3I), as well as the 
phosphorylation of the p47phox subunit of Nox2 at its activa-
tory site Ser359 and its membrane translocation (Figure 3J 
and 3K). Both the effects of adiponectin on Rac1 and p47phox 
were reversed by CC, suggesting that these effects involved 
AMPK signaling. Interestingly, the AMPK-mediated effects 
of adiponectin on Rac1 and p47phox activation/membrane 
translocation were independent of any change in Akt activ-
ity, as evidenced by Western blotting for phospho-Akt at its 
activation site Ser473, or protein kinase C-α phosphorylation 
status (Online Figure II).
These data suggest that adiponectin suppresses NADPH 
oxidases activity in the human myocardium in an AMPK-
dependent mechanism. Taken together with the observed 
positive association between myocardial NADPH oxidases 
activity and ADIPOQ gene expression in EpAT (Figure 2E), 
these findings suggest that myocardial O2− production may 
be driving (directly or indirectly) the expression of PPAR-γ/ 
ADIPOQ in EpAT.
Identifying a Novel, Redox Sensitive Signal From 
Cardiac Myocytes to EpAT
To explore the hypothesis that the release of a transferable 
factor from cardiac myocytes under conditions of increased 
oxidative stress may drive PPAR-γ/ADIPOQ expression in the 
EpAT, we exposed H9c2 cells to NADPH (100 μmol/L, the 
substrate of NADPH-oxidases) for 2 hours (Figure 4A), as a 
means to increase the production of O2− from NADPH oxi-
dases in these cells (Figure 4B and 4C). Exogenous NADPH 
increased intracellular NADPH by 25% (Online Figure III). 
The NADPH-simulated O2− in these cells was inhibited by 
≈60% using pan-Nox inhibitor Vas2870 and by 50% using 
the specific Nox2 inhibitor gp91-dstat (Figure 4). At the end 
of the 2-hour incubation period with NADPH, we cocul-
tured freshly collected rat EpAT with the stimulated H9c2 
cells for 16 hours (Figure 4A). At the end of the incubation 
Figure 1. Circulating adiponectin (AdN) is 
positively related with myocardial redox state 
in patients with ischemic heart disease. In the 
Clinical Associations Studies, high circulating 
AdN levels were paradoxically related with high 
myocardial nicotinamide adenine dinucleotide 
phosphate (NADPH)–stimulated superoxide (O2
−) 
(A) and high plasma malonyldialdehyde (MDA; a 
marker of systemic oxidative stress; B). There was 
no association of circulating adiponectin with plasma 
interleukin-6 (IL-6; C) or high-sensitivity C-reactive 
protein (hsCRP; D). High circulating adiponectin 
was also positively related with high plasma brain 
natriuretic peptide (BNP; E). Values are expressed as 
median (25th–75th percentile).
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period, we measured gene expression in the EpAT from co-
culture. There was no change in the expression of ADIPOQ, 
PPAR-γ, or CD36 genes in rat EpAT incubated with NADPH 
alone or cocultured with H9c2 cells without added NADPH 
(Figure 4D–4F). However, coculture of rat EpAT with H9c2 
cells prestimulated with NADPH resulted in a significant in-
crease in ADIPOQ gene expression (Figure 4D) as well as 
expression of PPAR-γ (Figure 4E) and its downstream target 
CD36 (Figure 4F). These effects were all prevented by the 
O2− scavenger PEG-SOD or the NADPH oxidases inhibitor 
Vas2870 (Figure 4D–4F). These findings indicate that in-
creased O2− production from H9c2 cells leads (either directly 
or indirectly via an intermediate factor) to upregulation of 
PPAR-γ/adiponectin expression in rat EpAT.
Figure 2. Genetically conferred increases in adiponectin (AdN) bioavailability are causally associated with lower nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase activity in the human myocardium. The total number of rs17366568G alleles 
(polymorphism in ADIPOQ gene) and rs266717T alleles (polymorphism in ADIPOQ gene promoter) had an additive effect on circulating 
AdN levels (A) and was associated with reduced NADPH–stimulated superoxide (O2
−) in human myocardium (B). The number of 
rs17366568G/rs266717T alleles was positively associated with higher ADIPOQ gene expression in thoracic adipose tissue (ThAT, C), 
but not associated in epicardial adipose tissue (EpAT; D). Patients with higher ADIPOQ (E) or peroxisome proliferator-activated receptor 
(PPAR)-γ (F) gene expression in EpAT also had higher NADPH-stimulated O2
− production in their myocardium. Higher myocardial NADPH-
stimulated O2
− was not associated with endogenous ADIPOQ gene expression in the heart (G), but was associated with higher gene 
expression of adiponectin receptor-1 (AdipoR1), but not of AdipoR2 or T-cadherin (CDH13) in human myocardial tissue (H). Values are 
expressed as median (25th–75th percentile). RLU indicates relative light units.
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As an alternative model to stimulate O2− generation in 
H9C2 cells in the above experiment, we repeated the same 
experimental design by using PMA 160 nmol/L instead of 
NADPH (Online Figure IV). We observed a similar upregu-
lation of ADIPOQ and PPAR-γ in rat EpAT that was in-
hibitable by Vas2870. However, the same effect was also 
observed in the absence of H9C2 cells, suggesting a direct 
effect of PMA on PPAR-γ signaling in the EpAT (Online 
Figure IV).
Myocardial Oxidation Products as Candidate 
Mediators of Inside-To-Outside Cardiac-Adipose 
Tissue Signaling.
Because O2− is a short-lived, highly reactive molecule, we 
hypothesized that other longer-lived reactive oxygen species 
rather than O2− itself (eg, H2O2) or even products of lipid oxi-
dation could act as transferable factors released from cardiac 
myocytes under oxidative stress conditions to exert a paracrine 
effect on EpAT. Incubation of human EpAT with H2O2 (100 
μmol/L) suppressed ADIPOQ gene expression (Online Figure 
VIA), suggesting that direct exposure of EpAT to H2O2 can-
not explain the observation in the Clinical Associations 
Studies that high myocardial oxidative stress is linked to high 
ADIPOQ expression in EpAT (Figure 2E).
Next, we examined whether products of lipid oxidation 
(formed under conditions of high myocardial oxidative stress) 
could modulate ADIPOQ expression in EpAT. We found that 
increased activity of NADPH oxidases in the human myo-
cardium leads to increased formation of common oxidation 
products, such as 4HNE and malonyldialdehyde, which form 
detectable adducts with proteins in the human myocardium 
(Figure 5A and 5B). 4HNE adducts are also rapidly increased 
in human myocardial tissue after ex vivo exposure to NADPH 
(100 μmol/L; Online Figure V). Incubation of human EpAT 
and ThAT with malonyldialdehyde had no impact on ADIPOQ 
(Figure 5C), PPAR-γ, or CD36 gene expression (Online Figure 
Figure 3. Effects of recombinant adiponectin (AdN) on myocardial redox state in humans. Ex vivo incubation of human myocardium 
with AdN (10 μg/mL) for 2 h resulted in increased phosphorylation of AMP-kinase (AMPK)-α at Thr172 (p-AMPK; A) leading to AMPK 
activation as assessed by the phosphorylation status of its downstream target acetyl-CoA carboxylase (ACC) at Ser79 (p-ACC; B), an 
effect reversed by compound C (CC; 10 μmol/L; A and B). AdN reduced superoxide (O2
−) production in human myocardium (C) and 
specifically nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity, as assessed by measuring the Vas2870-inhibitable 
(40 μmol/L) O2
− (D); both effects were reversed by CC (C and D). These effects of AdN on myocardial O2
− were also confirmed by 
dihydroethidium (DHE) staining; AdN reduced both total and Vas2870-inhibitable DHE fluorescence, and these effects were reversed by 
CC (E–G). Importantly, AdN prevented Rac1 activation (assessed by measuring the ratio of GTP-Rac1:total Rac1 [t-Rac1; H]) and reduced 
the membrane-bound fraction of Rac1 (m-Rac1; I); both effects were reversed by CC. Similarly, AdN prevented p47phox phosphorylation 
at its activatory site Ser359 (p-p47phox, J) and reduced the membrane-bound fraction of nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase subunit p47phox (m-p47phox; K) in an AMPK-dependent manner (as both effects were reversed by CC; J and K). A and B, 
AdN: n=7 to 13 per group; CC: 4 to 7 per group; (C, D, H, J, K) AdN, n=7 to 12; CC group, n=4 to 6; (E–I) n=3 to 4 per group. Values are 
expressed as fold change vs control group and shown as mean±SEM; *P<0.05, **P<0.01 vs control.
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VII) in either adipose tissue depot. By contrast, exposure of 
human EpAT to 4HNE induced a rapid 7-fold upregulation 
of ADIPOQ gene expression, an effect that was prevented by 
the PPAR-γ activity inhibitor T0070907 (Figure 5D). 4HNE 
also induced a respective 2-fold upregulation of PPAR-γ gene 
expression (Figure 5E) and a 5-fold increase of its down-
stream gene, CD36 (Figure 5F), the latter being prevented by 
the use of T0070907 (Figure 5F). Interestingly, the expression 
of PPAR-γ was significantly higher in EpAT than in ThAT, 
further supporting the notion that its expression in EpAT is 
largely driven by local signals released from the human myo-
cardium (Online Figure VIII). Taken together, these findings 
suggest that 4HNE exerts its effects on ADIPOQ gene expres-
sion not only by upregulating PPAR-γ but also by enhancing 
its downstream signaling (Figure 5E and 5F). Interestingly, 
4HNE had no effect on the expression of ADIPOQ, PPAR-
γ, and CD36 genes in remote sites of adipose tissue such as 
ThAT (Figure 5G–5I), supporting the hypothesis that 4HNE 
released from the human heart under conditions of increased 
oxidative stress may activate PPAR-γ signaling in EpAT via a 
paracrine mechanism.
Testing the Paracrine Effects of the Heart on EpAT 
Using Animal Models
To further explore whether a selective increase in myo-
cardial NADPH oxidases activity would lead to upregula-
tion of ADIPOQ gene expression in EpAT in vivo, we used 
a transgenic mouse model with cardiac myocyte–specific 
Figure 4. Activation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase in H9C2 cardiomyocytes triggers 
peroxisome proliferator-activated receptor gamma (PPAR-γ) signaling in rat pericardial fat: identifying a novel inside-to-outside 
signal. To examine whether under conditions of increased endogenous oxidative stress cardiac myocytes release a transferable factor 
able to affect the activation of PPAR-γ/adiponectin signaling in rat epicardial adipose tissue (EpAT), we exposed H9c2 cells (differentiated 
to cardiac myocytes) to NADPH 100 μmol/L for 2 h, whereas rat EpAT was conditioned ex vivo (A). After 2 h, the rat EpAT was transferred 
into the H9c2 wells and cocultured for an additional 16 h (A). At the end of the incubation period, gene expression was studied in the rat 
EpAT. Addition of NADPH to intact H9c2 cells grown on coverslips led to a striking increase of NADPH oxidase–derived superoxide (O2
−) 
that was partly inhibitable by either Vas2870 (a pan-Nox inhibitor) or gp91-dstat (a specific inhibitor of NOX2; B), as demonstrated by 
real-time monitoring using lucigenin-enhanced chemiluminescence. Coincubation of rat EpAT with H9c2 cardiac myocytes stimulated 
with NADPH resulted in an upregulation of ADIPOQ (C), PPAR-γ (D), and CD36 (E) in EpAT at 16 h. All these effects were prevented by 
polyethylene glycol (PEG)-SOD (300 U/mL) or vas2870 (10 nmol/L). The presence of unstimulated H9C2 cells or NADPH alone had no 
effect on the expression of ADIPOQ, PPAR-γ, or CD36 genes in the rat EpAT (C–E). Concentration of gp91-dstat was 50 μmol/L. Values 
are presented as mean±SEM. B, n=7; (C–E), n=7; *P<0.05 vs control group; ***P<0.0001 vs resting; †P<0.05 vs NADPH alone. DMEM 
indicates Dulbecco’s Modified Eagle Medium; RLU, relative light units; and SOD, superoxide dismutase.
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overexpression of human NOX2 (mNOX2-Tg; Online Figure 
IX)26 given the strong association of the latter with myocardial 
redox state in humans (Online Figure X).
Subcutaneous and pericardial AT was collected from 20-
week old male mNOX2-Tg and wild-type littermate mice. 
Overexpression of NOX2 in the myocardium of these mice 
(demonstrated in Online Figure IX) resulted in a significant 
increase of NADPH oxidases activity, as assessed by both the 
NADPH-stimulated O2− (Figure 6A) and Vas2870-inhibitable 
O2− production (Figure 6B). Overexpression of NOX2 also 
led to increased formation of 4HNE—but not of malonyldi-
aldehyde—adducts in the myocardium of mNOX2-Tg mice 
(Figure 6C and 6D). Interestingly, there was a striking upregula-
tion of ADIPOQ expression in pericardial but not in subcutane-
ous AT of the mNOX2-tg mice (Figure 6E). Myocardial NOX2 
overexpression also led to increased ADIPOQ gene expression 
in the myocardium (Figure 6F), but did not affect the expression 
of adiponectin receptors in the myocardium (Figure 6G).
Figure 5. Myocardial oxidation product 4-hydroxynonenal (4HNE) as a mediator of the inside-to-outside signal from the human 
myocardium to epicardial adipose tissue (EpAT). In human myocardium, increased nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidases activity (upper tertile of NADPH-stimulated O2
− in the Clinical Associations Studies) were associated with significantly 
greater 4HNE (A) and malonyldialdehyde (MDA; B) production. Incubation of EpAT and thoracic (ThAT) adipose tissue with MDA (1 
mmol/L) for 16 h had no significant impact on ADIPOQ gene expression (C). On the contrary, incubation of EpAT with 4HNE (30 µmol/L) 
for 16 h induced a striking increase in ADIPOQ (D), PPAR-γ (E) and CD36 (F). The effects of 4HNE on ADIPOQ and CD36 gene expression 
were reversed by the inhibitor of PPAR-γ activity, T0070907 (10 μmol/L; D and F). Importantly, 4HNE had no significant impact on the 
expression of ADIPOQ (G), PPAR-γ (H), or CD36 (I) genes in ThAT. Values are represented as fold change compared to control group 
(mean±SEM). A and B, n=4 per group; (C) n=5 per group; (D–I), n=5 to 8 per group, *P<0.05; **P<0.01 vs low myocardial NADPH oxidase 
activity (A and B) or control (C to I).
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To test whether the findings from the mNOX2-Tg mouse 
model could be replicated in a large animal, with typical EpAT 
distribution closer to the human one, we used rapid atrial pac-
ing in the pig to increase myocardial O2− production. As we 
have previously shown,4 rapid atrial pacing increases myocar-
dial NADPHoxidase activity in the left atrium as assessed by 
both the NADPH-stimulated O2− and the Vas2870-inhibitable 
O2− signal (Figure 7A and 7B). Activation of atrial NADPH 
oxidase resulted in increased myocardial formation of 4HNE 
but not of malonyldialdehyde adducts (Figure 7C and 7D, 
respectively) and led to a striking upregulation of ADIPOQ 
expression in EpAT attached to the left atrium, whereas there 
was no significant effect on ADIPOQ expression in the sub-
cutaneous adipose tissue (Figure 7E), or on the expression of 
endogenous adiponectin (Figure 7F) or adiponectin receptors 
(Figure 7G) in the left atrium. Taken together, these data dem-
onstrate that increased NADPH oxidase activity in the heart 
leads to upregulation of ADIPOQ expression specifically in 
EpAT. This corroborates the findings from our cell culture 
and ex vivo work in human atrial tissue and explains the 
positive associations between ADIPOQ expression in EpAT 
and NADPH oxidase activity in the underlying myocardium 
of patients with IHD.
Discussion
In the present study, we explore for the first time in humans, 
the role of adipose tissue-derived adiponectin in the regulation 
of myocardial redox state, through modulation of NADPH ox-
idase activity. Adiponectin prevents the phosphorylation and 
membrane translocation of p47phox and prevents Rac1 activa-
tion and membrane translocation, both key aspects of myocar-
dial NADPH oxidase activation. Under conditions of increased 
myocardial O2− generation, oxidation products such as 4HNE 
can act as signaling molecules from the heart, to activate adi-
ponectin release from EpAT in a PPAR-γ–dependent manner. 
This introduces the novel concept that, through the release of 
oxidation products, the human heart regulates key biological 
processes in adipose tissue by triggering rescue PPAR-γ sig-
naling leading to increased release of adiponectin, which then 
exerts cardioprotective effects. This novel inside-to-outside 
Figure 6. Testing the inside-to-outside paracrine 
effects of the heart on pericardial adipose 
tissue using a cardiomyocyte-specific Nox2-tg 
mouse model. In the cardiac myocyte–specific 
NOX2-transgenic mouse, myocardial nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidases 
were activated, as assessed by both the NADPH-
stimulated (A) and Vas2870-inhibitable superoxide 
(O2
−) signal (B), and by increased formation of 
4-hydroxynonenal (4HNE) protein adducts when 
compared with wild-type (wt) animals (C). There 
was no difference in the myocardial protein levels 
of malonyldialdehyde (MDA) adducts (D). Increased 
myocardial oxidative stress and 4HNE adducts 
formation in mNOX2-tg mice led to increased 
ADIPOQ gene expression in the fat attached to 
the heart (pericardial adipose tissue [PerAT]), but 
not in remote AT depots, eg, subcutaneous AT 
(ScAT; E). mNOX2-tg mice also had increased 
endogenous levels of ADIPOQ gene expression in 
myocardial tissue (F), but there was no difference 
in the myocardial gene expression levels of any of 
adiponectin receptors, T-cadherin (CDH13), AdipoR1 
and AdipoR2 (G); (A–E), n=5 to 6 per group; (F and G) 
n=9 to 10 per group, *P<0.05, **P<0.01 vs wt group. 
RLU indicates relative light units.
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signal may be a therapeutic target for the prevention and treat-
ment of redox-dependent cardiac diseases.
Myocardial redox state is a critical determinant of cardiac 
biology by modulating the function of ion channels, sarco-
plasmic reticulum calcium release channels, and myofilament 
proteins, in cardiac myocytes.1,2,27 O2− causes damage to cell 
membranes and leads to cardiac myocyte necrosis and apop-
tosis,2,28 whereas redox-sensitive signaling pathways control 
fibrotic and hypertrophic responses.29 NADPH oxidases and 
particularly Nox2 are major contributors to O2− production 
in the cardiovascular system,30 leading to the development of 
multiple cardiac pathologies such as heart failure,29 myocar-
dial hypertrophy,6 atrial fibrillation,3–5 and others. Nox2 ac-
tivation is dependent on Rac1 binding with GTP as well as 
p47phox phosphorylation and their subsequent translocation to 
the membrane to form the active catalytic complex of the en-
zyme.31 In this study, we demonstrate that systemic oxidative 
stress (as characterized by plasma malonyldialdehyde) is not 
significantly correlated with NADPH oxidase activity in hu-
man myocardium, confirming our previous observation that 
myocardial redox state is independent of markers of systemic 
oxidative stress and may be subjected to local, largely un-
known regulatory mechanisms.32
Human adipose tissue secretes a wide range of adipocyto-
kines able to affect myocardial biology.16,33 In addition, EpAT 
has been proposed to exert paracrine effects on the underlying 
epicardial coronaries.34 Given the close anatomic relationship 
between myocardium and EpAT in humans (with adipose tis-
sue penetrating into the heart muscle), it seems that EpAT ex-
erts paracrine effects on the underlying myocardium affecting 
its biology, as recently demonstrated in some elegant transla-
tional studies by Greulich et al.33 Adiponectin seems to have 
some direct effects on myocardial redox state in animal and 
cell culture models,28,35 but its role in the regulation of redox 
state in the human heart is unknown. It is also unclear whether 
adiponectin produced in EpAT has any paracrine role in the 
regulation of myocardial redox state, as suggested above.
In this study, we first evaluated the association between 
myocardial NADPH oxidases activity and circulating adipo-
nectin or the expression of adiponectin from EpAT or ThAT 
Figure 7. Testing the inside-to-outside paracrine 
effects of the heart on adipose tissue using a 
pig model of rapid atrial pacing (RAP). In a pig 
model of RAP, myocardial nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidases activity 
was significantly higher in the paced animals than in 
sham, as shown by both the NADPH-stimulated and 
Vas2870-inhibitable superoxide (O2
−) signal (A and B). 
RAP also increased formation of 4-hydroxynonenal 
(4HNE; but no malonyldialdehyde [MDA]) protein 
adducts (C and D) and upregulated ADIPOQ gene 
expression in epicardial AT (EpAT) but not in remote 
AT depots, eg, ScAT (E). There was no difference in 
endogenous ADIPOQ gene expression levels in the 
heart (F) or myocardial expression of adiponectin 
receptors (G) between sham-operated and RAP 
animals; all panels, n=5 per group, *P<0.05, **P<0.01 
vs sham group. RLU indicates relative light units.
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in a cohort of patients with IHD. Paradoxically, we observed a 
positive association between myocardial NADPH-stimulated 
O2− and circulating adiponectin as well as ADIPOQ gene 
expression in EpAT. A similar positive association was also 
observed between myocardial NADPH-stimulated O2− and 
adiponectin receptor AdipoR1. As this was the first study 
exploring the role of adiponectin in the regulation of myo-
cardial redox state in humans, we then tried to explore the 
direction of that unexpected association. By taking advantage 
of the genetic variability of ADIPOQ gene described in recent 
genome-wide association studies,24,36 we observed that geneti-
cally determined reduction of adiponectin levels is also as-
sociated with increased NADPH-stimulated O2− in the heart 
of patients with IHD (an association independent of other co-
variates, including BNP), implying that low adiponectin pro-
duction in the human AT is causally associated with higher 
myocardial NADPH oxidase activity. Using an ex vivo model 
of human myocardium, we observed that adiponectin had a 
direct inhibitory effect on myocardial NADPH oxidase activ-
ity (evidenced by a reduction in Vas2870-inhibitable myocar-
dial O2−) and that this effect is mediated by the activation of 
AMPK leading to reduced phosphorylation and membrane 
translocation of NADPH oxidase subunit p47phox in parallel to 
an AMPK-mediated suppression of Rac1 activation and mem-
brane translocation. This is the first study defining the molec-
ular mechanisms by which adiponectin suppresses NADPH 
oxidase activity in the human heart, but these findings are 
still unable to explain the positive association observed be-
tween myocardial redox state and ADIPOQ gene expression 
in EpAT in patients with IHD.
In advanced cardiovascular disease states (ie, heart fail-
ure), circulating adiponectin is significantly elevated.37 In 
cell culture studies,36 it was demonstrated that adipocytes 
respond to exogenous BNP (which is significantly elevated 
in heart failure) by upregulating ADIPOQ gene expression, 
and we have recently demonstrated that this stimulatory ef-
fect of BNP on human adipose tissue over-rides the suppres-
sive effect of inflammation on the expression and release of 
adiponectin.14 Although BNP seems to drive the circulating 
adiponectin level in the presence of heart failure, its role in 
the regulation of adipose tissue biology in the absence of 
heart failure seems less important.14 In this study, we dem-
onstrate that both circulating adiponectin and ADIPOQ gene 
expression in EpAT are positively correlated with myocar-
dial redox state (and specifically NADPH oxidase activity), 
independently of plasma BNP. Importantly, we demonstrate 
for the first time that products of oxidation, such as 4HNE, 
which is produced in the human heart under conditions of 
increased oxidative stress and can cross cellular membranes 
and act as signaling molecules,38 upregulate ADIPOQ gene 
expression in the human EpAT via a PPAR-γ–dependent 
mechanism. This novel concept was demonstrated by co-
culturing human EpAT with differentiated H9c2 cells af-
ter stimulation of cellular O2− production by supplying the 
NADPH oxidase with its substrate, ie, NADPH. This finding 
was then confirmed using a cardiac myocyte–specific NOX2 
transgenic mouse and a pig model of rapid atrial pacing (as 
means to increase NADPH oxidases activity and O2− genera-
tion in the atrial myocardium). Interestingly, in all models, 
it was consistently demonstrated that under conditions of 
increased myocardial O2− generation, the myocardium re-
leases transferable factor(s) (one of which seems to be 
4HNE), which then activates PPAR-γ signaling and upregu-
lates adiponectin expression specifically in the neighboring 
EpAT but not in other remote adipose tissue depots such 
as ThAT. Upregulation of adiponectin in EpAT represents a 
protective paracrine response of EpAT against myocardial 
oxidative stress, by inhibiting myocardial NADPH oxidase. 
With these findings, we document that EpAT hosts local 
defense mechanisms protecting the heart against oxidative 
stress (Online Figure XI).
Our study has some limitations. The patients included into 
the Clinical Associations and the ex vivo study arms were 
matched for age and sex, but there are some differences in 
other demographics and risk factor profile. Although we do 
not perform any direct comparisons between the 2 study arms, 
any extrapolations of the results from the ex vivo study arm 
to the Clinical Associations Studies should be made with 
caution. Moreover, the use of CC for pharmacological inhi-
bition of AMPK has been criticized because of possible non-
AMPK–specific effects39; nevertheless, it remains the most 
widely used cell-permeable AMPK inhibitor in cell/tissue 
experiments. We hypothesized that the lack of any effects 
of increased myocardial O2− generation/4HNE release on 
subcutaneous adipose tissue is because of its remote ana-
tomic site, but it could be also related to local depot-specific 
mechanisms maintaining increased ADIPOQ expression in 
this, preventing any further upregulation of ADIPOQ by 
exogenous 4HNE.14 Finally, although we have shown that 
exogenous NADPH increases intracellular NADPH and 
stimulates O2− generation from NADPH oxidases, these 
enzymes have their NADPH-binding site intracellular-
ly,40–42 and as NADPH is a large and charged molecule, it 
is unlikely to cross the plasma membranes by simple diffu-
sion. Therefore, the exact mechanism by which exogenous 
NADPH triggers O2− generation from NADPH oxidases in 
H9c2 cells used in the coculture experiment with rat epi-
cardial fat is unclear. The use of the PMA as a stimulus for 
O2− generation in H9C2 cells (which is know to stimulate 
NADPH oxidases in a protein kinase C-α–mediated mecha-
nism) has also direct effects on PPAR-γ signaling in the rat 
EpAT; therefore, the result from that experiment should be 
interpreted with caution.
In conclusion, we demonstrate for the first time that adi-
ponectin inhibits NADPH oxidase in the human myocardium 
via an AMPK/Rac1/p47phox-mediated signaling. We also show 
that under conditions of increased myocardial oxidative stress, 
the heart releases transferable mediators (eg, products of oxi-
dation such as 4HNE), which may diffuse to EpAT leading to 
PPAR-γ–dependent upregulation of adiponectin expression in 
EpAT. This feedback loop represents a novel defense mecha-
nism of the human heart against myocardial oxidative stress 
and may prove to be a rational therapeutic target in cardiac 
disease.
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What Is Known?
•	 Nicotinamide adenine dinucleotide phosphate oxidases are major 
contributors to myocardial oxidative stress in humans.
•	 Epicardial adipose tissue is an endocrine tissue that secretes active 
adipokines.
•	 In experimental animal models, adipose tissue–derived adiponectin 
has beneficial effects on cardiovascular system.
What New Information Does This Article Contribute?
•	 Adiponectin suppresses oxidative stress in the human heart.
•	 A novel inside-to-outside signal from the heart to it epicardial adipose 
tissue is described, introducing the concept of a cross talk between 
the human heart and its epicardial adipose tissue.
•	 Increased myocardial oxidative stress induces changes in the biology 
of the adjacent epicardial adipose tissue in humans, triggering local 
adiponectin expression in epicardial fat.
•	 Modulations of adiponectin production by the epicardial adipose 
tissue can be considered as a local defense mechanism to protect the 
heart from oxidative injury.
The role of epicardial adipose tissue in the physiology of the hu-
man heart is unclear. By using ex vivo models of human myo-
cardium from patients with ischemic heart disease as well as 
cell culture and animal models, we demonstrate that epicardial 
adipose tissue responds to the release of oxidation products 
from the heart by activating peroxisome proliferator-activated 
receptor-γ signaling, leading to increased local adiponectin bio-
synthesis (inside-to-outside signal). Local adiponectin released 
from epicardial adipose tissue may then exert paracrine effects 
on the human myocardium (outside-to-inside signal), suppress-
ing free radicals production by inhibiting nicotinamide adenine 
dinucleotide phosphate oxidases. Our data introduce the novel 
concept that human epicardial adipose tissue is in close, bidi-
rectional communication with the heart, and it may host defense 
mechanisms that protect the myocardium from oxidative as-
saults. These findings imply that targeting of epicardial adipose 
tissue may be a rational therapeutic strategy for cardioprotection 
in ischemic heart disease.
Novelty and Significance
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Detailed Methods 
 
Blood Sampling and Circulating Biomarkers Measurements 
Venous blood samples were obtained after 8 hours of fasting, at the morning of the operation for 
measurements of circulating biomarkers. After centrifugation at 2000 g / 4°C for 15 min, plasma or 
serum was collected and stored at −80 °C until assayed. Whole blood was also collected for 
genotyping. Serum adiponectin and interleukin 6 (IL-6), a marker of inflammation, were measured 
using enzyme linked immunosorbent assays (ELISA) (BioVendor, Brno, Czech Republic and R&D 
systems USA respectively). Plasma malonyldialdehyde (MDA), a marker of systemic oxidative stress, 
was quantified by using the TBARS fluorometric assay, as previously described.
1
 High sensitivity C-
reactive protein (hsCRP), another marker of inflammation, was measured by the high-sensitivity latex 
enhanced immunoturbidimetric assay (ADVIA, Bayer HealthCare LLC). Plasma BNP was quantified 
by chemiluminescent-microparticle immunoassay (Architect BNP, Abbott, Germany).  
 
DNA Extraction and Genotyping  
Genomic DNA was extracted from whole blood using standard methods (QIAamp DNA blood Midi 
kit, Qiagen). Genotyping for the rs17366568 (functional polymorphism in ADIPOQ gene) and 
rs266717 SNPs (functional polymorphism in ADIPOQ gene promoter) was performed using TaqMan 
probes (Applied Biosystems; Assay IDs: C-33187752-10 and C-8288442-10 respectively). The assay 
was run on an ABI StepOne Plus PCR system according to the manufacturer’s protocol.  
 
Harvesting of Human Myocardium and Adipose Tissue Samples  
During CABG, myocardial tissue samples were collected from the site of right atrial appendage 
(RAA) as we have previously described, and transferred into oxygenated (95% O2 / 5% CO2) ice-cold 
buffer. Samples of EpAT were harvested from the site of the right atrioventricular groove (inside the 
pericardial sac, attached to the heart), while thoracic adipose tissue (ThAT) samples were harvested 
from outside the pericardium (as “control” samples to the EpAT) and transferred in ice-cold 
phosphate buffer saline. All tissue samples were transferred immediately to the lab and either used for 
ex-vivo experiments or stored at -80°C for other studies as described below.  
 
Myocardial Superoxide Measurements 
Myocardial O2
.-
 production was measured in samples of right atrium appendages using lucigenin 
(5μmol/L)-enhanced chemiluminescence, as we have previously described.1 Myocardial tissue was 
homogenised in ice-cold Krebs HEPES Buffer pH 7.35 in the presence of protease inhibitor (Roche 
Applied Science, Indianapolis, IN) using a pre-cooled Polytron homogeniser. The contribution of 
NADPH oxidase activity to myocardial O2
.-
 production was quantified in the presence of NADPH 
100μmol/L. The use of homogenates allows us to overcome issues regarding penetration of NADPH 
(which is a polar molecule) into the cells or tissue. In certain ex vivo experiments with myocardial 
tissue, Vas2870 (40 μmol/L, a specific pan NADPH oxidase inhibitor2) was also used to get the 
Vas2870-inhibitable O2
.- 
signal as a more specific index of NADPH oxidase activity. In a pilot 
experiment comprising 10 RAA samples, we found that VAS2870 inhibitable O2
.-
 (pan-Nox inhibitor) 
was co-linear to the gp91dstat-inhibitable O2
.-
 (specific for Nox2) with r=0.8875 and P=0.0012. 
Therefore the use of vas2870 as an NADPH-oxidase inhibitor in the human right atrial appendage 
provides information mainly on Nox2-derived O2
.- 
. 
 
DHE Staining Method 
In situ O2
.-
 production was determined in right atrial appendage cryosections with the oxidative 
fluorescent dye dihydroethidium (DHE) as previously described.
3, 4
 Briefly, myocardial tissue was 
washed in ice-cold Krebs HEPES buffer and then cut into thin strips containing all myocardial layers. 
The tissue was first equilibrated for 20min in Krebs HEPES Buffer pH 7.35 at 37
o
C and then 
incubated for 2 hours in the presence or absence of recombinant full-length adiponectin 0.3 μmol/L 
(10 μg/ml, BioVendor) +/- CC (10 μmol/L). At the end of the incubation period tissue was collected 
and snap frozen in OCT.  Myocardial cryosections (30μm) were equilibrated in Krebs Hepes buffer 
with or without Vas2870 (40μmol/L) or peg-SOD (300 U/ml). Then the samples were incubated with 
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DHE (2μmol/L for 5 minutes). Fluorescence images of the myocardium (x63, Zeiss LSM 510 META 
laser scanning confocal microscope) were obtained from each myocardial tissue quadrant. In each 
case, segments of myocardial tissue (with and without Vas2870 or peg-SOD) were analyzed in 
parallel with identical imaging parameters. DHE fluorescence was quantified by using Image-Pro Plus 
software (Media Cybernetics), while all analyses were performed in a blinded fashion.  
 
RNA Isolation and Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) Samples of 
adipose tissue and myocardial tissue samples were snap frozen in QIAzol (Qiagen, Stanford, CA) and 
stored at -80
o
C until processed. RNA was extracted by using the RNeasy Micro or Mini kit (Qiagen). 
RNA was converted into complementary DNA (Quantitect Rev. Transcription kit - Qiagen), then 
subjected to qPCR using TaqMan probes (Applied Biosystems, Foster City, CA). The reactions were 
performed in triplicate in 384-well plates, using 5 ng of cDNA per reaction, on an ABI 7900HT Fast 
Real-Time PCR System (Applied Biosystems). The efficiency of the reaction in each plate was 
determined based on the slope of the standard curve; relative expression of ADIPOQ gene was 
calculated using the Pfaffl method 
5
. 
For the clinical studies, PPIA (cyclophilin) and PGK1 were used as housekeeping genes for adipose 
tissue and myocardial tissue, respectively. The Assay IDs of the Taqman probes used were ADIPOQ 
(adiponectin gene): Hs00605917_m1; ADIPOR1: Hs01114951_m1, ADIPOR2: Hs00226105_m1, 
CDH13: Hs01004530_m1, CD36: Hs01567185_m1, PPARG: Hs01115513_m1, PGK1: 
Hs00943178_g1, PPIA: Hs04194521_s1, CYBB(NOX2), NOX4, CYBA (P22PHOX), NCF1 
(P47PHOX), NCF2(P67PHOX).  
For the rat epicardial adipose tissue (see below), PPIA was used as housekeeping gene. The Assay 
IDs of the Taqman probes used were PPIA: Rn00690933_m1, ADIPOQ: Rn00595250_m1, PPARG: 
Rn00440945_m1, CD36: Rn00560963_s1. 
For the mouse model (see below), PPIA and actin-alpha (ACTA) were used as housekeeping genes for 
adipose tissue and myocardial tissue, respectively. The Assay IDs of the Taqman probes used were 
ACTA: Mm00808218_g1, ADIPOQ: Mm00456425_m1, ADIPOR1: Mm01291334_mH, ADIPOR2: 
Mm01184032_m1, CDH13: Mm00490584_m1, PPIA: Mm02342429_g1. 
For the pig model, PPIA and actin-beta (ACTB) were used as housekeeping genes for adipose tissue 
and myocardial tissue, respectively. The assay IDs of the Taqman probes used were ACTB: 
Ss03376160_u1, ADIPOQ: Ss03384375_u1, ADIPOR1: Ss03378803_u1, ADIPOR2: 
Ss03391825_g1, CDH13: Ss03386756_u1, PPIA: Ss03394782_g1.  
 
Western Blots in human myocardial samples 
To investigate adiponectin-AMPK signaling axis and its effects on NADPH oxidase activity, western 
immunoblotting was used to examine the direct effects of adiponectin on phospho(Th172)-AMPKa, 
total AMPKa, phospho(Ser473)-Akt, pan-Akt, phospho(Ser79)-acetyl-CoA carboxylase (ACC) and 
total ACC (antibodies by Cell Signaling, Danvers, MA), Nox1, Nox2 (antibodies by BD Transduction 
Laboratories), Nox4, Nox5 (antibodies by Abcam, Cambridge, UK), phospho(Ser359)-p47phox, total 
p47phox, p67phox (antibodies by Cell Signaling), and total Rac1 (antibody by Merck Millipore, 
Billerica, MA) protein levels in human myocardium incubated ex-vivo. Selected myocardial tissue 
samples from Clinical Associations Studies were also used to evaluate the content of 4-
hydroxynonenal (4HNE) and malonyldialdehyde (MDA) adducts, the two most common lipid 
oxidation products (formed when reactive oxygen species react with lipid membranes, antibodies by 
Abcam) in the presence of high or low myocardial NADPH-stimulated O2
.-
 generation. Briefly, 
myocardial tissue samples were homogenized for 30 seconds using a pre-cooled electric Polytron 
homogenizer in 300 μl of lysis buffer (Invitrogen, UK) containing a protease and phosphatase 
inhibitor cocktail (Roche Applied Science). Homogenates were spun at 13,000 rpm for 10 minutes, at 
4 ºC. The protein concentration of the supernatants was then measured using the BCATM Protein 
Assay kit (Pierce, UK). Protein lysates were separated on 4-12% gradient SDS-NuPAGE gel 
(Invitrogen, UK), and proteins transferred to polyvinylidene difluoride membranes (Amersham, UK 
Ltd.), followed by blocking with 5% powdered skimmed milk. The membranes were incubated with 
the respective primary antibodies overnight and immunodetection of the primary antibodies was 
performed with horseradish-peroxidase-conjugated secondary antibodies (Promega) and enhanced 
4 
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chemifluorescence (Amersham Bioscience UK Ltd.) and quantified in relation to the house-keeping 
protein, GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA).  
 
Measurement of Myocardial Rac1 Activation and Membrane Translocation Experiments 
Rac1 activation was evaluated by a commercially available affinity precipitation assay using the 
PAK1-PBD conjugated glutathione agarose beads (Millipore, Temecula, USA)
3
. To estimate 
membrane translocation of Rac1 and p47phox, we performed differential centrifugation for isolation 
of membrane proteins, and membrane-translocated Rac-1 and p47phox proteins were determined by 
Western immunoblotting as previously described.
3
 
 
Measurement of intracellular NADP/NADPH levels 
For measurements of intracellular NADP/NADPH levels, a commercially available fluorometric assay 
was used (Abcam kit, Cambridge, UK). Following the 18 hour treatment, H9C2 cells were washed 3x 
with PBS and then lysed. Twenty five μl of the lysates were loaded into a black walled 96-well plate 
for processing. Finally, 75ul of NADPH reaction mixture was added to initiate the reaction according 
to manufacturer’s instructions and after 45 minutes the fluorescence was measured at 
Ex/Em=540/590nm. The assay kit provides measurements of intracellular NADPH, NADP and total 
NADPH/NADP separately. 
 
Animal studies 
Generating the mouse model: The cardiomyocyte-specific NOX2 overexpressing mouse model 
(mNOX2-tg) was generated in the laboratory of Ajay Shah.
6
 The expression of the human 1.8kb NOX2 
cDNA was driven by the mouse myosin light chain-2 (MLC-2v) promoter. Transgenic founders were 
backcrossed for >10 generations onto a C57BL/6 background. 
   The decision to overexpress human NOX2 in these mice was based on our findings in Clinical 
Associations Studies in which NOX2 gene expression was strongly correlated with myocardial O2
.-
 in 
the human right atrium appendages (Online Figure X), while its activation dependents on p47
phox
 
phosphorylation/membrane translocation and Rac1 activation. On the other hand, unlike Nox2, Nox4 
does not require Rac1/p47phox membrane translocation to be activated, and exploring its role in this 
setting was beyond the scope of the current study.  
  Pig model: In 10 Dutch Landrace pigs (62±3 kg), anesthesia was induced with Zoletil (5-8mg/kg 
i.m.) and Thiopenthal (5-15mg/kg i.v.). After intubation, anesthesia was maintained by intravenous 
infusion of Midazolam (1.0mg/kg/h), Sufentanyl (4mg/kg/h) and Propofol (2.5-10mg/kg/h). An 
endocardial lead (Capsurefix 5568, Medtronic, Minneapolis, MN) was implanted in the right atrium 
and connected to a subcutaneous pacemaker (Itrel II, Medtronic, Minneapolis, MN). Healthy pigs 
(61±2 kg) served as a control group. After one week recovery, the pacemaker was switched on at a 
rate of 10Hz for 5 weeks. The ventricular rate was controlled by digoxin 10µg/kg for 1 week, 
followed by 5µg/kg for 4 weeks. Digoxin was discontinued 3 days before the sacrifice experiment in 
order to reach plasma levels <0.5μg/ml. At sacrifice, animals were anesthetized as described above 
and the heart was excised via a left lateral incision. Epicardial adipose tissue was collected from the 
posterior left atrium, close to the AV ring. For comparison, subcutaneous fat was taken from the 
incision in the thorax.     
 
Power calculations 
Sample size calculations were based on previous data from our laboratory. For the clinical studies, we 
estimated that a total number of 200 subjects would allow us to detect a 0.31 (or 7.5%) difference in 
log(myocardial NADPH-stimulated O2
.-
) between the extreme tertiles of plasma adiponectin with an 
α=0.05, a power of 0.9, and an assumed standard deviation of 0.57. For the ex vivo experiments, 
sample size calculations were performed on the basis of pilot experiments and we estimated that with 
a minimum of 5 pairs of samples (serial samples from the same myocardial tissue), we would be able 
to identify a change in log(myocardial NADPH-stimulated O2
.-) of 0.84 (or 20%) with an α=0.05, a 
power 0.9, and a standard deviation for a difference in the response of the pairs of 0.44. Power 
calculations for the animal experiments were based on pilot data on adiponectin expression from 
epicardial adipose tissue; for the transgenic mice experiments, we estimated that with a minimum of 5 
mice per group, we would be able to identify a change in adiponectin gene expression of 0.51 (2fold 
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change) with an α=0.05, a power 0.9, and a standard deviation for a difference in the response of the 
pairs of 0.22. Similarly, for the pig model of atrial pacing, we estimated that with a minimum of 5 
pigs per group, we would be able to identify a change in adiponectin gene expression from epicardial 
adipose tissue of 0.91 (3fold change) with an α=0.05, a power 0.9, and a standard deviation for a 
difference in the response of the pairs of 0.39. 
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Supplemental Tables 
 
Online Table I: Multivariable models of myocardial NADPH-stimulated O2
.- 
and serum adiponectin 
Model for myocardial NADPH-stimulated O2
.-
 
Univariate analysis 
Variable Correlation coefficient* P-value 
Log(serum adiponectin) 0.361 0.0001 
Log(plasma BNP) -0.045 0.601 
Age  0.179 0.031 
Male gender -0.220 0.007 
Smoking status 0.153 0.064 
Left ventricular ejection fraction -0.213 0.023 
Multivariable analysis (R
2
 for the model: 0.211, P=0.001) 
Variable Standardized beta P-value 
Log(serum adiponectin) 3.802 0.001 
Log(plasma BNP) -0.08 0.465 
Age  0.063 0.526 
Male gender -0.086 0.419 
Smoking status 0.034 0.734 
Left ventricular ejection fraction -0.163 0.137 
 
 
Model for circulating adiponectin 
Univariate analysis 
Variable Correlation coefficient* P-value 
Log(NADPH stimulated O2
.-
) 0.361 0.0001 
Log(plasma BNP) 0.257 0.0001 
Male gender  -0.175 0.008 
Age  0.224 0.001 
Body mass index -0.126 0.07 
Diabetes mellitus -0.128 0.05 
Hypercholesterolaemia  
 
-0.175 0.009 
Multivariable analysis (R
2
 for the model: 0.215, P=0.0001) 
Variable Standardized beta P-value 
Log(NADPH stimulated O2
.-
) 0.210 0.016 
Log(plasma BNP) 0.229 0.008 
Male gender  -0.210 0.017 
Age  -0.042 0.082 
Body mass index -0.148 0.225 
Diabetes mellitus -0.067 0.423 
Hypercholesterolaemia  -0.102 0.628 
BNP: Brain natriuretic peptide; *Spearman’s or Pearson’s correlation coefficient as appropriate 
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Supplemental Figures and Figure Legends  
Online Figure I 
 
Obesity and adiponectin/PPAR-γ gene expression in thoracic and epicardial adipose tissue.  In 
patients of Clinical Associations Studies (clinical cohort of 247 patients undergoing coronary artery 
bypass grafting), there was a significant inverse association between increased body mass index 
(BMI) and adiponectin gene (ADIPOQ) expression from thoracic adipose tissue (AT, Panel A). A 
trend towards lower PPAR-γ gene expression from thoracic AT with increased BMI was observed too 
but this did not reach statistical significance (Panel B). Abdominal obesity as assessed by the waist to 
hip ratio was also associated with lower ADIPOQ (Panel C) and PPAR-γ gene expression (Panel D) 
from thoracic AT. On the other hand, BMI and waist to hip ratio were not associated with adiponectin 
(Panel E & G) or PPAR-γ gene expression (Panel F & H) in epicardial AT. p-values are derived from 
ANOVA. 
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Online Figure II 
 
Effects of recombinant adiponectin on the expression of NADPH oxidase subunits and protein 
kinase C-a phosphorylation. Human myocardium was incubated ex-vivo for 2h in the presence or 
absence of recombinant human adiponectin (10μg/mL). Adiponectin did not lead to a significant 
increase in activity of Akt in this tissue, as assessed by Western blotting for phospho-Ser473 Akt, 
even though a positive trend was observed (Panel A). There was also no effect of adiponectin on the 
phosphorylation of protein kinase C-α at Thr497 (PKCα, Panel B), suggesting that its effects on 
NADPH oxidase were independent of any effects on Akt or PKCα signalling. Moreover, adiponectin 
did not have any effects on the protein levels of Nox2 and Nox4 isoforms or the protein levels of 
NADPH oxidase subunits, namely p22
phox
, p47
phox
 and p67
phox
 (Panel C-D). n=10-12 for the 
adiponectin group and n=5-7 for the compound C; NS vs control group.   
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Online Figure III 
 
 
Changes of intracellular NADP/NADPH levels after incubation with exogenous NADPH. H9C2 
cells were incubated with / without NADPH 100μmol/L for 18h, in conditions that mimic the co-
culture experiments. Then the cells were washed thoroughly and lysed to measure intracellular 
concentration of NADPH, NADP and total NADP/NADPH using a fluorometric assay. There was a 
significant increase of both NADPH (by ~25%, A) and NADP (by ~25%, B), with the total 
NADP/NADPH being increased by ~45% (C) compared to control (**P<0.001 vs control). N=6 
independent experiments. 
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Online Figure IV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Co-culture of rat epicardial adipose tissue and H9C2 cells pre-stimulated with PMA. To examine 
whether under conditions of increased endogenous oxidative stress cardiomyocytes release a 
transferable factor able to affect the activation of PPAR-γ/adiponectin signalling in rat epicardial 
adipose tissue (EpAT), we exposed H9c2 cells to Phorbol-12-Myristate-13-Acetate (PMA, 160 
nmol/L) while rat EpAT was conditioned ex vivo (Panel A). After 2h, the rat EpAT was transferred 
into the H9c2 wells and co-cultured for an additional 16 hours (Panel A). At the end of the incubation 
period, gene expression of PPAR-γ and ADIPOQ were studied in the rat EpAT. Addition of PMA to 
intact H9c2 cells grown on coverslips led to a striking increase of NADPH oxidases-derived 
superoxide (O2
.-
, Panel B), as demonstrated by real-time monitoring using lucigenin-enhanced 
chemiluminescence. Co-incubation of rat EpAT with H9c2 cardiomyocytes stimulated with PMA 
resulted in an up-regulation of ADIPOQ (Panel C) and PPAR-γ expression (Panel D) in EpAT at 16h. 
These effects were prevented by VAS2870 (10nmol/L). However, PMA alone had a similar direct 
effect on ADIPOQ and PPAR-γ expression in EpAT even in the absence of H9C2 cells. DMEM: 
Dulbecco's Modified Eagle Medium; n=7 independent experiments; *p<0.05 vs control group.  
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Online Figure V 
 
Short-term NADPH stimulation of human myocardium increases the formation of 4-HNE 
adducts. Human myocardium from patients undergoing coronary artery bypass grafting operation 
was incubated ex vivo for 16h +/- NADPH 100μmol/L (as a means to induce superoxide generation 
from NADPH oxidase). This interaction resulted in increased formation of 4-hydroxynonenal protein 
adducts (by-products of lipid oxidation) in myocardial tissue (Panel A). n=5 independent experiments; 
*p<0.05 vs control group.  
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Online Figure VI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ex vivo incubations of human epicardial adipose tissue with H2O2. Exposure of human epicardial 
adipose tissue (EAT) to H2O2 (100 μmol/L) for 16 h led to a significant reduction in adiponectin 
(ADIPOQ) gene expression, with no significant changes in PPARγ or CD36 expression (n=8 
independent experiments, *p<0.05 vs control). 
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Online Figure VII 
  
 
 
Ex-vivo incubation of epicardial (EpAT) and thoracic (ThAT) adipose tissue with 
malonyldialdehyde (MDA). EpAT and ThAT from 6 patients undergoing coronary artery bypass 
grafting was incubated ex-vivo for 16 hours in the presence or absence of MDA 1mM and used for 
gene expression studies. MDA did not have any effects on the relative expression levels of PPAR-γ 
and CD36 gene in either EpAT (Panels A-B) or ThAT (Panels C-D). n=5-6 independent experiments; 
NS: non significant vs control group. 
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Online Figure VIII 
 
 
Comparison of peroxisome proliferator activated receptor-γ (PPAR-γ) expression and 
activation between human adipose tissue depots. Adipose tissue samples of patients with coronary 
artery disease, were used to compare the expression of PPAR-γ and its downstream mediator CD36 in 
epicardial (EpAT) vs thoracic adipose tissue (ThAT). Both the expression of PPAR-γ (A) and its 
downstream molecule CD36 (B) were higher in EpAT compared to ThAT.  
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Online Figure IX 
 
Mouse model of cardiomyocyte-specific overexpression of human NOX2. There was no difference 
in the expression of murine NOX2 in the heart of mNOX2-tg vs the wild type (wt) animals (Panel A). 
On the contrary, mNOX2-tg mice were over-expressing human NOX2 in their cardiomyocytes, which 
was not expressed in the wt mice (Panel B). n=9-10 per group; NS: non-significant; ****p<0.0001 vs 
wt. 
  
16 
CIRCRES/2015/307856DR1   Antonopoulos A et al   
 
 
 
Online Figure X 
 
 
NOX2 expression and O2
.-
 generation in the human right atrium appendages (RAA). High NOX2 
gene expression in human RAA was significantly associated with increased resting O2·
-
 (A), NADPH-
stimulated O2·
-
 (B) and Vas2870-inhibitable O2·
-
 (C) in the same tissue.   
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Online Figure XI 
 
 
 
Schematic representation of the bi-directional signalling between epicardial adipose tissue and 
the myocardium. The cross-talk between epicardial adipose tissue (EpAT) and the myocardium 
involves the release of oxidation products from the heart (4-hydroxynonenal- 4HNE) able to trigger 
peroxisome proliferator activated receptor (PPAR)-γ – induced expression of adiponectin (AdN) in 
EpAT, which may suppress NADPH oxidases activity in the underlying heart muscle in a paracrine 
way, via an AMPK (AMP kinase) –dependent activation of Rac1 and phosphorylation of p47phox 
subunits of NADPH oxidase. AT: Adipose Tissue. 
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